CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Yuhan Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Yuhan Corp
74, Noryangjin-ro, Dongjak-gu
Phone: +82 28280181p:+82 28280181 SEOUL, 06927  South Korea Ticker: 000100000100
Business Summary
Yuhan Corp is a Korea-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical Business segment manufactures and sells non-prescription drugs, such as analgesics, anti-inflammatory drugs, probiotics, nutritional supplements, and wound-healing agents, as well as prescription drugs, including treatments for diabetes, hyperlipidemia, hypertension, hepatitis, acquired immunodeficiency syndrome (AIDS), bone marrow cancer, cough suppressants, and breast cancer. The Overseas Business segment engages in the export of AIDS treatment intermediates. The Healthcare Business segment provides household goods, such as bleach. Additionally, the Company sells licenses. The Company sells its products in both domestic and overseas markets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
2842 Specialty cleaning, polishing, and sanitation preparations
6794 Patent owners and lessors
2819 Industrial inorganic chemicals, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-President, Chief Executive Officer, Director Wuk JeCho 71 1/1/2023 4/1/2009
Co-President, Director Yeol HongKim 67 3/15/2024 3/15/2024
Vice President Byeong ManLee 67 3/1/2024 1/1/2015
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ImmuneOncia Therapeutics Inc. Wins-tower 6F, 15, Pangyo-ro 228beon-gil Seongnam-si Gyeonggi-do South Korea

Business Names
Business Name
0001
000100
000105
000107
ImmuneOncia Therapeutics Inc.
Yuhan Corporation

General Information
Number of Employees: 1,594 (As of 12/31/2015)
Outstanding Shares: 73,294,945 (As of 2/5/2026)
Shareholders: 141,237
Stock Exchange: KRX
Fax Number: +82 28280050


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 13, 2026